High Intensity Focused Ultrasound (HIFU) Ablation System Study
Suspended
ProRhythm, Inc.
Phase 3
2006-04-01
The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is
effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best
medical therapy with FDA approved antiarrhythmic drugs.
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
Completed
Abbott Medical Devices
N/A
2006-09-01
The CABANA pilot study is designed to test the hypothesis that the treatment strategy of
percutaneous left atrial catheter ablation for the purpose of the elimination of atrial
fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or
anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
Completed
Duke Clinical Research Institute
N/A
2006-09-01
The CABANA pilot study is designed to test the hypothesis that the treatment strategy of
percutaneous left atrial catheter ablation for the purpose of the elimination of atrial
fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or
anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
Completed
St. Jude Medical
N/A
2006-09-01
The CABANA pilot study is designed to test the hypothesis that the treatment strategy of
percutaneous left atrial catheter ablation for the purpose of the elimination of atrial
fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or
anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
Completed
Mayo Clinic
N/A
2006-09-01
The CABANA pilot study is designed to test the hypothesis that the treatment strategy of
percutaneous left atrial catheter ablation for the purpose of the elimination of atrial
fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or
anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
